Device/Diagnostics Quarterly Deal Statistics, Q2 2013

A look at financing, M&A, and alliance activity, April–June 2013

Similar to Q1’s deal dollars and volume, device companies raised $1.06 billion through 45 transactions; Bayer HealthCare’s $1 billion purchase of Conceptus was the only device M&A in Q2 to exceed the billion-dollar mark. Diagnostics players raised a total of $2.9 billion during the second quarter, a huge increase over Q1 due to Thermo Fisher Scientific’s $2.46 billion follow-on offering to support its $15.2 billion April acquisition of Life Technology, another Q2 outlier in the M&A category.

In the second quarter of 2013, device companies raised $1.06 billion (45 transactions), on par with the $1.1 billion amassed in the previous quarter for about the same number of deals. (See Exhibit 1.) Late-stage venture financing again led, bringing in $384 million. Top fundraiser Proteus Digital Health Inc. grossed $63 million in a Series F round from corporate backers Oracle Corp., Otsuka Pharmaceutical Co. Ltd., Novartis AG, and return investor Sino Portfolio. [See Deal] Proteus has brought in $180 million since its 2001 inception and in July 2012 received FDA approval for its ingestible sensor device (see[A#01120806010]), capable of communicating physiologic and behavioral data to caregivers via a wireless signal contained in the sensor. The diagnostic imaging field had a decent showing from three firms completing late-stage raises: a $36 million Series D by SuperSonic Imagine SA (ultrasound) [See Deal], a $25 million Series Cby Topera Medical Inc. (3-D cardio display) [See Deal], and a $17 million Series D from ViewRay Inc. (MRI-guided cancer radiotherapy). [See Deal]

Exhibit 1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Deals Shaping The Industry, May 2025

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By 

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Deals In Depth: April 2025

 
• By 

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By 

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By 

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.